Clinical Trial

Post-Market Study to Assess iTind Safety in Comparison to UroLift

Study acronym: MT-08
Recruiting
View on ClinicalTrials.gov →
Summary
The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-08-04
notable Enrollment increased: 206 -> 256 participants 2026-08-04
notable Primary completion pushed: 2026-06-30 -> 2027-07-15 2026-08-04
minor Completion moved earlier: 2031-12-31 -> 2030-05-31 2026-08-04
Trial Details
NCT Number NCT04757116
Lead Sponsor Olympus Corporation of the Americas
Collaborators: Olympus Europe SE & Co. KG
Conditions Benign Prostatic Hyperplasia (BPH)
Enrollment 256 participants
Start Date 2022-09-26
Primary Completion 2027-07-15 (estimated)
Study Completion 2030-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-03